Vericel Corp VCEL
We take great care to ensure that the data presented and summarized in this overview for Vericel Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VCEL
View all-
Black Rock Inc. New York, NY7.97MShares$382 Million0.01% of portfolio
-
Brown Capital Management LLC Baltimore, MD4.95MShares$237 Million4.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.41MShares$164 Million0.0% of portfolio
-
State Street Corp Boston, MA3.21MShares$154 Million0.01% of portfolio
-
Conestoga Capital Advisors, LLC2.33MShares$112 Million1.77% of portfolio
-
Rtw Investments, LP New York, NY1.61MShares$77.1 Million1.34% of portfolio
-
Gw&K Investment Management, LLC Boston, MA1.23MShares$58.8 Million0.56% of portfolio
-
Loomis Sayles & CO L P1.11MShares$53.1 Million0.08% of portfolio
-
Macquarie Group LTD Australia, C31.08MShares$51.9 Million0.06% of portfolio
-
Geode Capital Management, LLC Boston, MA1.06MShares$51 Million0.01% of portfolio
Latest Institutional Activity in VCEL
Top Purchases
Top Sells
About VCEL
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at VCEL
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 20
2024
|
Jonathan Mark Hopper Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,000
-14.68%
|
$490,000
$49.99 P/Share
|
May 20
2024
|
Jonathan Mark Hopper Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+12.8%
|
$100,000
$10.95 P/Share
|
May 17
2024
|
Michael Halpin Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,195
+36.41%
|
$20,780
$4.93 P/Share
|
May 16
2024
|
Dominick Colangelo President and CEO |
SELL
Open market or private sale
|
Direct |
17,500
-7.35%
|
$822,500
$47.85 P/Share
|
May 16
2024
|
Dominick Colangelo President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+6.84%
|
$52,500
$3.02 P/Share
|
May 15
2024
|
Dominick Colangelo President and CEO |
SELL
Open market or private sale
|
Direct |
17,500
-7.35%
|
$857,500
$49.67 P/Share
|
May 15
2024
|
Dominick Colangelo President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+6.84%
|
$52,500
$3.02 P/Share
|
May 01
2024
|
Alan L Rubino |
BUY
Exercise of conversion of derivative security
|
Direct |
3,200
+11.85%
|
-
|
May 01
2024
|
Kevin F Mclaughlin |
BUY
Exercise of conversion of derivative security
|
Direct |
3,200
+21.19%
|
-
|
May 01
2024
|
Steven C Gilman |
BUY
Exercise of conversion of derivative security
|
Direct |
3,200
+22.54%
|
-
|
May 01
2024
|
Heidi Hagen |
BUY
Exercise of conversion of derivative security
|
Direct |
3,200
+14.65%
|
-
|
May 01
2024
|
Paul K Wotton |
BUY
Exercise of conversion of derivative security
|
Direct |
3,200
+9.64%
|
-
|
May 01
2024
|
Robert L Md Zerbe |
BUY
Exercise of conversion of derivative security
|
Direct |
3,200
+10.74%
|
-
|
May 01
2024
|
Lisa Wright |
BUY
Exercise of conversion of derivative security
|
Direct |
3,200
+26.19%
|
-
|
Apr 30
2024
|
Dominick Colangelo President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,445
+3.8%
|
$330,785
$13.95 P/Share
|
Apr 18
2024
|
Dominick Colangelo President and CEO |
SELL
Open market or private sale
|
Direct |
17,500
-8.22%
|
$770,000
$44.59 P/Share
|
Apr 18
2024
|
Dominick Colangelo President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+7.6%
|
$52,500
$3.02 P/Share
|
Apr 17
2024
|
Dominick Colangelo President and CEO |
SELL
Open market or private sale
|
Direct |
17,500
-8.22%
|
$805,000
$46.47 P/Share
|
Apr 17
2024
|
Dominick Colangelo President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+7.6%
|
$52,500
$3.02 P/Share
|
Apr 09
2024
|
Alan L Rubino |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+12.72%
|
$12,000
$4.12 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 407K shares |
---|---|
Bona fide gift | 16.4K shares |
Open market or private sale | 300K shares |
---|---|
Payment of exercise price or tax liability | 40K shares |
Bona fide gift | 24.2K shares |